Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-23
2011-08-23
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S199000
Reexamination Certificate
active
08003669
ABSTRACT:
The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.
REFERENCES:
patent: 6043366 (2000-03-01), Adam et al.
patent: 6071925 (2000-06-01), Adam et al.
patent: 6113527 (2000-09-01), Adam et al.
patent: 6166209 (2000-12-01), Adam et al.
patent: 6172067 (2001-01-01), Ito et al.
patent: 6258825 (2001-07-01), Ozaki et al.
patent: 6277991 (2001-08-01), Hohlweg et al.
patent: 6340681 (2002-01-01), Ito
patent: 6410561 (2002-06-01), Shinkai et al.
patent: 6423725 (2002-07-01), Ito et al.
patent: 6465478 (2002-10-01), Ito et al.
patent: 6635653 (2003-10-01), Goehring et al.
patent: 6642247 (2003-11-01), Adam et al.
patent: 2001/0041746 (2001-11-01), Kyle et al.
patent: 2002/0035110 (2002-03-01), Bentley et al.
patent: 2002/0049212 (2002-04-01), Ito et al.
patent: 2002/0128288 (2002-09-01), Kyle et al.
patent: 2003/0008886 (2003-01-01), Goehring et al.
patent: 2003/0013874 (2003-01-01), Goehring et al.
patent: 2003/0018041 (2003-01-01), Goehring et al.
patent: 2003/0027834 (2003-02-01), Goehring et al.
patent: 2003/0055087 (2003-03-01), Shinkai et al.
patent: 2003/0078278 (2003-04-01), Ito et al.
patent: 2003/0078279 (2003-04-01), Ito et al.
patent: 2003/0176701 (2003-09-01), Adam et al.
patent: 2003/0216401 (2003-11-01), Bentley et al.
patent: 2004/0024218 (2004-02-01), Barlocco et al.
patent: 0 997 464 (2000-05-01), None
patent: 1 122 257 (2001-08-01), None
patent: 1 420 020 (2004-05-01), None
patent: 10-212290 (1998-08-01), None
patent: 11-228575 (1999-08-01), None
patent: 2000-26466 (2000-01-01), None
patent: 2000-53686 (2000-02-01), None
patent: 2001-39974 (2001-02-01), None
patent: 2001-58991 (2001-03-01), None
patent: 98/54168 (1998-12-01), None
patent: 99/29696 (1999-06-01), None
patent: 99/36421 (1999-07-01), None
patent: 99/48492 (1999-09-01), None
patent: 99/59997 (1999-11-01), None
patent: 00/06545 (2000-02-01), None
patent: 00/08013 (2000-02-01), None
patent: 00/14067 (2000-03-01), None
patent: 00/27815 (2000-05-01), None
patent: 00/31061 (2000-06-01), None
patent: 01/29029 (2001-04-01), None
patent: 01/39767 (2001-06-01), None
patent: 01/39775 (2001-06-01), None
patent: 02/10169 (2002-02-01), None
patent: 02/26714 (2002-04-01), None
patent: 02/085291 (2002-10-01), None
patent: 02/085354 (2002-10-01), None
patent: 02/085355 (2002-10-01), None
patent: 02/085361 (2002-10-01), None
patent: 03/000677 (2003-01-01), None
US 6,172,075, 01/2001, Adam et al. (withdrawn)
Aetna Intellihealth website “Narcolepsy” “http://www.intelihealth.com/IH/ihtIH/WSIHW000/24597/24598/210412.html?d=dmtHealthAZ” online: accessed Aug. 22, 2010.
European Office Action issued May 5, 2010 in corresponding EP Application No. 03 715 566.
Laura McAtee et al., “High-Affinity, Non-Peptide Agonists for the ORL1 (Orphanin FQ/Nociceptin) Receptor”. Chemtracts—Organic Chemistry, 14(9), pp. 513-517, 2001.
James Bunzow et al., “Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ of κ opioid receptor type”. FEBS Lett. vol. 347, pp. 284-288, 1994.
Catherine Mollereau et al., “ORL1, a novel member of the opioid receptor family”. FEBS Lett. vol. 341, pp. 33-38, 1994.
Jean-Claude Meunier, “Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor”. European Journal of Pharmacology vol. 340, pp. 1-15, 1997.
Jeffrey S. Mogil et al., “The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family”. Pharmacological Reviews, vol. 53, No. 3, pp. 381-415, 2001.
Jean-Claude Meunier et al., “Isolation and structure of the endogenous agonist of opioid receptor-like ORL1receptor”. Letters to Nature, vol. 377, pp. 532-535. 1995.
John Sandin et al., “Short Communication: Nociceptin/Orphanin FQ Microinjected into Hippocampus Impairs Spatial Learning in Rats”. European Journal of Neuroscience, vol. 9, pp. 194-197, 1997.
Toshiya Manabe et al., “Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors”. Nature, vol. 394, pp. 577-581, 1998.
Francois Jenck et al., “Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress”. Proc. Natl. Acad. Sci:, vol. 94, pp. 14854-14858, 1997.
Anja Koster et al., “Targeted disruption of the orphanin FQ
ociceptin gene increases stress susceptibility and impairs stress adaptation in mice”. Proc. Natl. Acad. Sci., vol. 96, pp. 10444-10449, 1999.
Molecular Medicine, vol. 34, No. 3, pp. 355-365, 1997 and partial English translation.
Charles N. Allen, “Orphanin-FQ/Nociceptin (OFQ/N) Modulates the Activity of Suprachiasmatic Nucleus Neurons”. The Journal of Neuroscience, vol. 19(6), pp. 2152-2160, 1999.
Rainer K. Reinscheid et al., “Orphanin FQ: A Neuropeptide That Activates an Opioidlike G Protein-Coupled Receptor”. Science, vol. 270, pp. 792-794, 1995.
Girolamo Calo et al., “Pharmacology of nociceptin and its receptor: a novel therapeutic target”. British Journal of Pharmacology, vol. 129, pp. 1261-1283, 2000.
Francois Jenck, et al, “A synthetic agonist at the orphanin FQ
ociceptin receptor ORL1: Anxiolytic profile in the rat”, Proceedings of the National Academy of Sciences (2000), vol. 97, pp. 4938-4943.
Drew Dawson and Stuart Maxwell Amstron, “Chronobiotics-Drugs That Shift Rhythms”, Pharmacology and Therapeutics (1996), vol. 69, pp. 15-36.
Yvan Touitou, André Bogdan, “Promoting adjustment of the sleep-wake cycle by chronobiotics”, Physiology & Behavior (2007), vol. 90, pp. 294-300.
Hashiba et al., “Characterisation and comparison of novel ligands for the nocieceptin/orphanin FQ receptor”, Naunyn-Schmiedeberg's Archives of Pharmacology (2001), vol. 363, pp. 28-33.
Roever et al., “High-Affinity, Non-peptide Agonists for ORL1 (Orphanin FQ/Nociceptin) Receptor”, Journal of Medicinal Chemistry (2000), vol. 43, pp. 1329-1338.
Wichmann, Jurgen et al., “8-Acenaphthen-1-yl-1-phenyl-1,3,8-trizaz-spiro[4,5]decan-4-one derivatives as orphanin FQ receptor agonists”, Bioorganic & Medicinal Chemistry Letters (1999), vol. 9, pp. 2343-2348.
Minoguchi Masanori
Teshima Koji
Desai Rita
Mitsubishi Tanabe Pharma Corporation
O'Dell David K
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Remedy for sleep disturbance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedy for sleep disturbance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedy for sleep disturbance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726580